N/A
Completed N=61
Sapphire II PRO US Clinical Study
Source: ClinicalTrials.gov NCT03052530 ↗Enrolled (actual)
61
Serious AEs
0.0%
Results posted
Apr 2018
Primary outcomePrimary: Number of Participants With Device Procedural Success — 59 Participants
Summary
A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device procedural success of the Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters in subjects with stenotic coronary arteries or bypass grafts during percutaneous coronary intervention.
Sixty (60) subjects will be treated at up to 5 U.S. sites with the Sapphire II PRO diameters 1.0 and 1.25 mm PTCA dilatation catheters to pre-dilate coronary arteries or bypass grafts during their index procedure. All subjects will be screened according to the protocol inclusion and exclusion criteria and will be followed through hospital discharge.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Device Procedural Success |
59 | — |
| SECONDARY Number of Participants With In-hospital Major Adverse Cardiac Events (MACE) |
1 | — |
| SECONDARY Number of Participants With In-hospital Stent Thrombosis (ST) Within the Target Vessel |
— | — |
| SECONDARY Number of Participants With Clinically Significant Arrhythmias (Requiring Intervention) |
— | — |
Eligibility Criteria
Clinical Inclusion Criteria:
- Subject is ≥ 18 years of age.
- Subject or a legally authorized representative must provide written informed consent prior to any study related procedures.
- Subject must agree not to participate in any other clinical study during hospitalization for the index procedure that would interfere with the endpoints of this study.
- Subjects must have a single or double vessel coronary artery disease and clinical evidence of ischemic heart disease, such as stable / unstable angina or silent ischemia.
Angiographic Inclusion Criteria
- Subject must have de novo or restenotic lesion(s) in native coronary arteries or bypass grafts that are suitable for percutaneous coronary intervention. An embolic protection device must be used in all Saphenous venous grafts (SVG) interventions performed during the index procedure.
- A maximum of two lesions, including at least one target lesion, in up to two coronary arteries.
- Target and non-target lesions must be located in different coronary arteries or bypass grafts.
- Target lesion(s) must have a diameter stenosis of ≥70% by visual estimation and may include chronic total occlusions (CTO)
- Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success.
Clinical Exclusion Criteria:
- Subject with a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot be adequately pre-medicated.
- Subject with known diagnosis of an acute myocardial infarction (AMI) within 72 hours prior to index procedure.
- Subject with known pregnancy or is nursing. Women of child- bearing potential should have a documented negative pregnancy test within 7 days before index procedure.
- Planned or actual target lesion treatment with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure.
- A serum creatinine level > 2.0 mg/dl within seven days prior to index procedure.
- Cerebrovascular accident (CVA) within the past 6 months.
- Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months.
- Subject has a known left ventricular ejection fraction (LVEF) 2.0 mm in diameter.
- Non-target lesion to be treated during the index procedure meets any of the following criteria:
- Located within a bypass graft (venous or arterial)
- Left main location
- Chronic total occlusion
- Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1 stent)
- Treatment not deemed a clinical angiographic success
Data sourced from ClinicalTrials.gov (NCT03052530). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.